Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Under what circumstances would you choose palopegteriparatide over teriparatide in patients with chronic hypoparathyroidism?
Related Questions
Is there a role for calcitriol in dialysis patients regardless of PTH level?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
Do oral contraceptives lower bone mineral density in women with hypothalamic amenorrhea by lowering IGF-1?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
What is the utility of near-infrared autofluorescence (NIRAF) imaging during parathyroid surgery?
Do you use bone turnover markers to assess medical adherence in patients treated for osteoporosis?
Would you favor oral bisphosphonates over intravenous formulations for patients with hormone sensitive prostate cancer and androgen deprivation therapy (ADT) related osteopenia?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?
